2024

• Hocknull, K., Geiger, B., Bartlett, M., Colledge-Frisby, S., Shand, F., Day, C., Jauncey, M., Roxburgh, A. (2024). Improving assessment and management of suicide risk among people who inject drugs: A mixed methods study conducted at the Medically Supervised Injecting Centre, Sydney. Drug and Alcohol Review. [More Information]
• Stirling, R., Hudson, S., Ross, J., Deans, E., Tibbetts, J., Day, C., Deacon, R., Dunlop, A., Lintzeris, N. (2024). Understanding the research capacity of alcohol and other drugs services in New South Wales, Australia. Drug and Alcohol Review, 43(1), 265-277. [More Information]

2023

• Roxburgh, A., Clark, N., Livingston, M., Dietze, P., Nielsen, S., Cogger, S., Bartlett, M., Day, C., Latimer, J., Jauncey, M. (2023). The impact of COVID-19 public health measures on attendance and overdose at supervised injecting facilities in Australia. Public Health, 224, 90-97. [More Information]

2022

• Coupland, H., Day, C., Haber, P., Pritchard-Jones, J., McKee, K., George, J., McCaughan, G. (2022). Client resistance to hepatitis C treatment initiation in opioid agonist treatment clinics in Sydney, Australia: A qualitative study. Drug and Alcohol Review, 41(3), 706-714. [More Information]
• Moensted, M., Day, C. (2022). Operationalising cultural competency in the context of substance use treatment: a qualitative analysis. Drugs: education, prevention & policy, 29(1), 76-84. [More Information]
• Reid, S., Day, C., White, N., Harrison, C., Haber, P., Bayram, C. (2022). Opioid prescribing in general practice: an Australian cross-sectional survey. BMC Primary Care, 23(1). [More Information]
• Coupland, H., Henderson, C., Pritchard-Jones, J., Kao, S., Sheils, S., Nagy, R., O’Donnell, M., Haber, P., Day, C. (2022). Setting foot in private spaces: extending the hepatitis C cascade of care to automatic needle/syringe dispensing machines, a mixed methods study. Harm Reduction Journal, 19(1), 56. [More Information]
• Uthurralt, N., McGlinn, A., O'Donnell, M., Haber, P., Day, C. (2022). The impact of a 24-hour syringe dispensing machine on a face-to-face needle and syringe program and targeted primary healthcare clinic. Australian and New Zealand Journal of Public Health, 46(4), 524-526. [More Information]
• Day, C., Salmon, A., Jauncey, M., Bartlett, M., Roxburgh, A. (2022). Twenty-one years at the Uniting Medically Supervised Injecting Centre, Sydney: addressing the remaining questions. Medical Journal of Australia, 217(8), 385-387. [More Information]

2021

• Roxburgh, A., Jauncey, M., Day, C., Bartlett, M., Dietze, P., Nielsen, S., Latimer, J., Clark, N. (2021). Adapting harm reduction services during COVID-19: lessons from the supervised injecting facilities in Australia. Harm Reduction Journal, 18(1), 20. [More Information]
• Tran, V., Reid, S., Roxburgh, A., Day, C. (2021). Assessing drug consumption rooms and longer term (5 year) impacts on community and clients. Risk Management and Healthcare Policy, 14, 4639-4647. [More Information]
• Coupland, H., Moensted, M., Reid, S., White, B., Eastwood, J., Haber, P., Day, C. (2021). Developing a model of care for substance use in pregnancy and parenting services, Sydney, Australia: Service provider perspectives. Journal of Substance Abuse Treatment, 131, 108420. [More Information]
• Haber, P., Riordan, B., Day, C., Monds, L., Baillie, A., Reid, S., Mills, K., Doyle, M., Teesson, M., Morley, K., Mooney-Somers, J., Lintzeris, N., Stapinski, L., Marel, C., Conigrave, K., Winter, D. (2021). New Australian guidelines for the treatment of alcohol problems: an overview of recommendations. Medical Journal of Australia, 215(Suppl 7), S3-S32. [More Information]
• Nielsen, S., Sanfilippo, P., Belackova, V., Day, C., Silins, E., Lintzeris, N., Bruno, R., Grebely, J., Lancaster, K., Ali, R., et al (2021). Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. Addiction, 116(6), 1482-1494. [More Information]
• Winter, D., White, N., Geiger, B., Haber, P., Day, C. (2021). Should we be using e-vouchers to compensate research participants? Acceptability among opioid agonist treatment clients. Drug and Alcohol Review, 40(7), 1356-1357. [More Information]
• Riordan, B., Winter, D., Haber, P., Day, C., Morley, K. (2021). What are people saying on social networking sites about the Australian alcohol consumption guidelines? Medical Journal of Australia, 214(3), 105-1.07E+03. [More Information]

2020

• Al-Ansari, B., Noroozi, A., Thow, A., Day, C., Mirzaie, M., Conigrave, K. (2020). Alcohol treatment systems in Muslim majority countries: Case study of alcohol treatment policy in Iran. International Journal of Drug Policy, 80, 102753. [More Information]
• Day, C., White, N. (2020). Gender-Specific Online Content Is Important and Timely for Women Receiving Treatment for Substance Use Disorders. Journal of Women's Health, 29(5), 605-606. [More Information]
• Moensted, M., Day, C. (2020). Health and social interventions in the context of support and control: The experiences of marginalised people who use drugs in Australia. Health and Social Care in the Community, 28(4), 1152-1159. [More Information]
• Day, C., White, B., Reid, S., Fowler, M., Black, K. (2020). Integration of a contraception clinic into an opioid treatment setting to improve contraception knowledge, accessibility and uptake: a pilot study. Australian and New Zealand Journal of Public Health, 44(5), 360-362. [More Information]
• Moensted, M., Day, C., Buus, N. (2020). Youth Practitioners’ Perspectives on Building Agency and Supporting Transitions with and for Young People Experiencing Disadvantage. Journal of Applied Youth Studies, 3(2023-05-04 00:00:00), 293-310. [More Information]

2019

• Belackova, V., Silins, E., Salmon, A., Jauncey, M., Day, C. (2019). "Beyond Safer Injecting"-Health and Social Needs and Acceptance of Support among Clients of a Supervised Injecting Facility. International Journal of Environmental Research and Public Health, 16(11), 1-12. [More Information]
• Day, C., Moensted, M. (2019). A health justice partnership in inner-city Sydney : attendance patterns and client perceptions : final report.
• Al-Ansari, B., Thow, A., Mirzaei, M., Day, C., Conigrave, K. (2019). Alcohol policy in Iran: Policy content analysis. International Journal of Drug Policy, 73, 185-198. [More Information]
• Dowsett, M., Islam, M., Ganora, C., Day, C., Lee, K., Dawson, A., Joseph, T., White, A., Freeburn, B., Conigrave, K. (2019). Asking young Aboriginal people who use illicit drugs about their healthcare preferences using audio-computer-assisted self-interviewing. Drug and Alcohol Review, 38(5), 482-493. [More Information]
• Makdessi, C., Day, C., Chaar, B. (2019). Challenges faced with opioid prescriptions in the community setting - Australian pharmacists' perspectives. Research in Social and Administrative Pharmacy, 15(8), 966-973. [More Information]
• Belackova, V., Salmon, A., Day, C., Ritter, A., Shanahan, M., Hedrich, D., Kerr, T., Jauncey, M. (2019). Drug consumption rooms: A systematic review of evaluation methodologies. Drug and Alcohol Review, 38(4), 406-422. [More Information]
• Ross, L., Haber, P., Day, C. (2019). Identification of smoking status in the Census is needed, but what about the healthcare system? Australian and New Zealand Journal of Public Health, 43(1), 96-96. [More Information]
• Power, J., Salmon, A., Latimer, J., Jauncey, M., Day, C. (2019). Overdose Risk and Client Characteristics Associated With the Injection of Buprenorphine at a Medically Supervised Injecting Center in Sydney, Australia. Substance Use and Misuse, 54(10), 1646-1653. [More Information]
• Belackova, V., Salmon, A., Jauncey, M., Day, C. (2019). Safer injecting facilities - is the research there? A comment on Caulkins et al (2019). Addiction, 115(4), 784-785. [More Information]
• Butler, K., Larney, S., Day, C., Burns, L. (2019). Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system. Drug and Alcohol Review, 38(3), 264-269. [More Information]

2018

• Ezard, N., Cecilio, M., Clifford, M., Baldry, E., Burns, L., Day, C., Shanahan, M., Dolan, K. (2018). A managed alcohol program in Sydney, Australia: Acceptability, cost-savings and non-beverage alcohol use. Drug and Alcohol Review, 37(Suppl. 1), S184-S194. [More Information]
• Kovitwanichkanont, T., Day, C. (2018). Prescription Opioid Misuse and Public Health Approach in Australia. Substance Use and Misuse, 53(2), 200-205. [More Information]
• Spaulding, A., Eldridge, G., Chico, C., Morisseau, N., Drobeniuc, A., Fils-Aime, R., Day, C., Hopkins, R., Jin, X., Chen, J., et al (2018). Smoking in Correctional Settings Worldwide: Prevalence, Bans, and Interventions. Epidemiologic Reviews, 40(1), 82-95. [More Information]
• Day, C., Coupland, H., Moensted, M., Burns, L. (2018). The need for more research and considered debate regarding women's only treatment services: a comment on Neale et al 2018. Addiction, 113(9), 1752. [More Information]
• Reid, S., Day, C., Bowen, D., Minnis, J., Ludlow, J., Jacobs, S., Gordon, A., Haber, P. (2018). Vertical transmission of hepatitis C: Testing and health-care engagement. Journal of Paediatrics and Child Health, 54(6), 647-652. [More Information]
• Day, C. (2018). Women Need Less Judgment and More Support to Access Contraception. Journal of Women's Health, 27(10), 1187-1188. [More Information]

2017

• Fortier, E., Alavi, M., Bruneau, J., Micallef, M., Perram, J., Sockalingam, S., Dunlop, A., Balcomb, A., Day, C., Treloar, C., Haber, P., et al (2017). Depression, Anxiety, and Stress among People with Chronic Hepatitis C Virus Infection and a History of Injecting Drug Use in New South Wales, Australia. Journal of Addiction Medicine, 11(1), 10-18. [More Information]
• Larney, S., Hickman, M., Guy, R., Grebely, J., Dore, G., Gray, R., Day, C., Kimber, J., Degenhardt, L. (2017). Estimating the number of people who inject drugs in Australia. BMC Public Health, 17(757), 1-7. [More Information]
• Butler, K., Day, C., Sutherland, R., van Buskirk, J., Breen, C., Burns, L., Larney, S. (2017). Hepatitis C testing in general practice settings: A cross-sectional study of people who inject drugs in Australia. International Journal of Drug Policy, 47, 102-106. [More Information]

2016

• Breen, C., Burns, L., Day, C. (2016). Alcohol Use Among Reproductive Aged Women: The Role of the Clinical Psychologist. Australian Clinical Psychologist, 2(1), e20106.
• Al-Ansari, B., Day, C., Thow, A., Conigrave, K. (2016). Civil alcohol policy in Muslim majority countries: need for global tools, expert support and local partnerships. Addiction, 111(10), 1718-1719. [More Information]
• White, B., Haber, P., Day, C. (2016). Community attitudes towards harm reduction services and a newly established needle and syringe automatic dispensing machine in an inner-city area of Sydney, Australia. International Journal of Drug Policy, 27, 121-126. [More Information]
• Day, C., Shanahan, M., Wand, H., Topp, L., Haber, P., Rodgers, C., Deacon, R., Walsh, N., Kaldor, J., Van Beek, I., et al (2016). Development of immunity following financial incentives for hepatitis B vaccination among people who inject drugs: A randomized controlled trial. Journal Of Clinical Virology, 74, 66-72. [More Information]
• Al-Ansari, B., Thow, A., Day, C., Conigrave, K. (2016). Extent of alcohol prohibition in civil policy in Muslim majority countries: the impact of globalization. Addiction, 111(10), 1703-1713. [More Information]
• Mitchell, S., Bungay, V., Day, C., Mooney-Somers, J. (2016). Has the experience of Hepatitis C diagnosis improved over the last decade? An analysis of Canadian women's experiences. The Canadian Journal of Nursing Research, 48(1), 21-28. [More Information]
• Black, K., Day, C. (2016). Improving Access to Long-Acting Contraceptive Methods and Reducing Unplanned Pregnancy Among Women with Substance Use Disorders. Substance Abuse: Research and Treatment, 10(Suppl. 1), 27-33. [More Information]
• Doyle, J., Grebely, J., Spelman, T., Alavi, M., Matthews, G., Thompson, A., Dore, G., Hellard, M., Kaldor, J., Marks, P., et al (2016). Quality of life and social functioning during treatment of recent hepatitis C infection: A multi-centre prospective cohort. PloS One, 11(6). [More Information]
• Heyes, C., Schofield, T., Gribble, R., Day, C., Haber, P. (2016). Reluctance to Accept Alcohol Treatment by Alcoholic Liver Disease Transplant Patients: A Qualitative Study. Transplantation Direct, 2(10), 1-9. [More Information]
• Day, C., White, B., Haber, P. (2016). The impact of an automatic syringe dispensing machine in inner-city Sydney, Australia: No evidence of a 'honey-pot' effect. Drug and Alcohol Review, 35(5), 637-643. [More Information]
• Stirling, R., Day, C. (2016). The policy and practices of New South Wales drug treatment providers in responding to the possession of illicit substances on premises. Drug and Alcohol Review, 35(5), 644-649. [More Information]
• Grebely, J., Alavi, M., Micallef, M., Dunlop, A., Balcomb, A., Phung, N., Weltman, M., Day, C., Treloar, C., Bath, N., Haber, P., et al (2016). Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: The ETHOS Study. Addiction, 111(2), 311-319. [More Information]

2015

• Keats, J., Micallef, M., Grebely, J., Hazelwood, S., Everingham, H., Hazelwood, S., Jones, T., Bath, N., Treloar, C., Dore, G., et al (2015). Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia. International Journal of Drug Policy, 26(10), 999-1006. [More Information]
• Alavi, M., Micallef, M., Fortier, E., Dunlop, A., Balcomb, A., Day, C., Treloar, C., Bath, N., Haber, P., Dore, G., et al (2015). Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: The ETHOS study. Journal of Viral Hepatitis, 22(11), 914-925. [More Information]
• Treloar, C., Rance, J., Bath, N., Everingham, H., Micallef, M., Day, C., Hazelwood, S., Grebely, J., Dore, G. (2015). Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia. International Journal of Drug Policy, 26(10), 992-998. [More Information]
• Haber, P., Day, C., Topp, L., Shanahan, M., Wand, H., van Beek, I., Maher, L. (2015). Hepatitis B vaccination for people who inject drugs. The Lancet, 385(9963), 115. [More Information]
• Alavi, M., Spelman, T., Matthews, G., Haber, P., Day, C., Van Beek, I., Walsh, N., Yeung, B., Bruneau, J., Petoumenos, K., et al (2015). Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. International Journal of Drug Policy, 26(10), 976-983. [More Information]
• Fowler, C., Rossiter, C., Sherwood, J., Day, C. (2015). New Understandings of Mothering: Mothers in an Abstinence-Based Drug Treatment Program. International Journal of Mental Health and Addiction, 13(2), 173-184. [More Information]
• Day, C. (2015). Public health responses to drug and alcohol use. In Paul Haber, Carolyn Day, Michael Farrell (Eds.), Addiction Medicine: Principles and Practice, (pp. 36-47). Melbourne: IP Communications.
• Bui, J., Day, C., Hanrahan, J., Winstock, A., Chaar, B. (2015). Senior nurses' perspectives on the transfer of opioid substitution treatment clients from clinics to community pharmacy. Drug and Alcohol Review, 34(5), 495-498. [More Information]
• Fortier, E., Alavi, M., Micallef, M., Dunlop, A., Balcomb, A., Day, C., Treloar, C., Bath, N., Haber, P., Dore, G., et al (2015). The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study. International Journal of Drug Policy, 26(11), 1094-1102. [More Information]
• Butler, K., Day, C., Dietze, P., Bruno, R., Alati, R., Burns, L. (2015). The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia. Journal of Substance Abuse Treatment, 58, 90-94. [More Information]
• Reid, S., Day, C. (2015). Women and drugs. In Paul Haber, Carolyn Day, Michael Farrell (Eds.), Addiction Medicine: Principles and Practice, (pp. 379-387). Melbourne: IP Communications.

2014

• Fowler, C., Reid, S., Minnis, J., Day, C. (2014). Experiences of mothers with substance dependence: Informing the development of parenting support. Journal of Clinical Nursing, 23(19-20), 2835-2843. [More Information]
• Deacon, R., Hines, S., Curry, K., Tynan, M., Day, C. (2014). Feasibility of ambulatory withdrawal management delivered in a NSW drug health service and correlates of completion. Australian Health Review, 38(2), 186-189. [More Information]
• Shand, F., Day, C., Rawlinson, W., Degenhardt, L., Martin, N., Nelson, E. (2014). Hepatitis C testing and status among opioid substitution treatment clients in New South Wales. Australian and New Zealand Journal of Public Health, 38(2), 160-164. [More Information]
• Treloar, C., Rance, J., Haber, P., Bath, N., Day, C., Dore, G., Grebely, J., Honey, C., Krahn, M., Lodge, M., et al (2014). How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting. International Journal of Drug Policy, 25(5), 865-870. [More Information]
• Haber, P., Day, C. (2014). Overview of Substance Use and Treatment from Australia. Substance Abuse, 35(3), 304-308. [More Information]
• Islam, M., Conigrave, K., Day, C., Nguyen, Y., Haber, P. (2014). Twenty-year trends in benzodiazepine dispensing in the Australian population. Internal Medicine Journal, 44(1), 57-64. [More Information]

2013

• Topp, L., Day, C., Wand, H., Deacon, R., Van Beek, I., Haber, P., Shanahan, M., Rodgers, C., Maher, L. (2013). A randomised controlled trial of ï¬�nancial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia. Preventive Medicine, 57(4), 297-303. [More Information]
• Islam, M., Topp, L., Conigrave, K., White, A., Haber, P., Day, C. (2013). Are primary health care centres that target injecting drug users attracting and serving the clients they are designed for? A case study from Sydney, Australia. International Journal of Drug Policy, 24(4), 326-332. [More Information]
• Alavi, M., Grebely, J., Micallef, M., Dunlop, A., Balcomb, A., Day, C., Treloar, C., Bath, N., Haber, P., Dore, G. (2013). Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study. Clinical Infectious Diseases, 57(Suppl 2), S62-S69. [More Information]
• Md Mofizul, M., Topp, L., Conigrave, K., Day, C. (2013). Deï¬�ning a service for people who use drugs as 'low-threshold': What should be the criteria? International Journal of Drug Policy, 24(3), 220-222. [More Information]
• Chaar, B., Wang, H., Day, C., Hanrahan, J., Winstock, A., Fois, R. (2013). Factors influencing pharmacy services in opioid substitution treatment. Drug and Alcohol Review, 32(4), 426-434. [More Information]
• Islam, M., Taylor, A., Smyth, C., Day, C. (2013). General health of opioid substitution therapy clients. Internal Medicine Journal, 43(12), 1335-1338. [More Information]
• Islam, M., Topp, L., Iversen, J., Day, C., Conigrave, K., Maher, L. (2013). Healthcare utilisation and disclosure of injecting drug use among clients of Australia's needle and syringe programs. Australian and New Zealand Journal of Public Health, 37(2), 148-154. [More Information]
• Islam, M., Topp, L., Conigrave, K., Day, C. (2013). Opioid substitution therapy clients' preferences for targeted versus general primary health-care outlets. Drug and Alcohol Review, 32(2), 211-214. [More Information]
• Topp, L., Islam, M., Day, C. (2013). Relative efficacy of cash versus vouchers in engaging opioid substitution treatment clients in survey-based research. Journal of Medical Ethics, 39(4), 253-256. [More Information]
• Mofizul Islam, M., Day, C., Conigrave, K., Topp, L. (2013). Self-perceived problem with alcohol use among opioid substitution treatment clients. Addictive Behaviors, 38(4), 2018-2021. [More Information]
• Islam, M., Topp, L., Conigrave, K., Haber, P., White, A., Day, C. (2013). Sexually transmitted infections, sexual risk behaviours and perceived barriers to safe sex among drug users. Australian and New Zealand Journal of Public Health, 37(4), 311-315. [More Information]
• Islam, M., Shanahan, M., Topp, L., Conigrave, K., White, A., Day, C. (2013). The cost of providing primary health-care services from a needle and syringe program: A case study. Drug and Alcohol Review, 32(3), 312-319. [More Information]

2012

• Deacon, R., Topp, L., Wand, H., Day, C., Rodgers, C., Haber, P., van Beek, I., Maher, L. (2012). Correlates of Susceptibility to Hepatitis B among People Who Inject Drugs in Sydney, Australia. Journal of Urban Health, 89(5), 769-778. [More Information]
• Alavi, M., Grebely, J., Matthews, G., Petoumenos, K., Yeung, B., Day, C., Lloyd, A., van Beek, I., Kaldor, J., Hellard, M., Haber, P., et al (2012). Effect of pegylated interferon alfa-2a treatment on mental health during recent hepatitis C virus infection. Journal of Gastroenterology and Hepatology, 27(5), 957-965. [More Information]
• Day, C., Demirkol, A., Tynan, M., Curry, K., Hines, S., Lintzeris, N., Haber, P. (2012). Individual versus team-based case-management for clients of opioid treatment services: An initial evaluation of what clients prefer. Drug and Alcohol Review, 31(4), 499-506. [More Information]
• Islam, M., Topp, L., Conigrave, K., White, A., Reid, S., Grummett, S., Haber, P., Day, C. (2012). Linkage into specialist hepatitis C treatment services of injecting drug users attending a needle syringe program-based primary healthcare centre. Journal of Substance Abuse Treatment, 43(4), 440-445. [More Information]
• Mofizul Islam, M., Topp, L., Day, C., Dawson, A., Conigrave, K. (2012). Primary healthcare outlets that target injecting drug users: Opportunity to make services accessible and acceptable to the target group. International Journal of Drug Policy, 23(2), 109-110. [More Information]
• Mofizul Islam, M., Topp, L., Day, C., Dawson, A., Conigrave, K. (2012). The accessibility, acceptability, health impact and cost implications of primary healthcare outlets that target injecting drug users: A narrative synthesis of literature. International Journal of Drug Policy, 23(2), 94-102. [More Information]
• Islam, M., Topp, L., Conigrave, K., van Beek, I., Maher, L., White, A., Rodgers, C., Day, C. (2012). The reliability of sensitive information provided by injecting drug users in a clinical setting: Clinician-administered versus audio computer-assisted self-interviewing (ACASI). AIDS Care - Psychological and Socio-Medical Aspects of AIDS/Hiv, 24(12), 1496-1503. [More Information]

2011

• Mofizul Islam, M., Grummett, S., White, A., Reid, S., Day, C., Haber, P. (2011). A primary healthcare clinic in a needle syringe program may contribute to HIV prevention by early detection of incident HIV in an injecting drug user. Australian and New Zealand Journal of Public Health, 35(3), 294-295. [More Information]
• Day, C., Topp, L. (2011). Commentary on Turner et al. (2011): Significant global scale-up of harm reduction interventions and pragmatic research approaches needed to prevent hepatitis C transmission. Addiction, 106(11), 1989-1990. [More Information]
• Day, C., Mofizul Islam, M., White, A., Reid, S., Hayes, S., Haber, P. (2011). Development of a nurse-led primary healthcare service for injecting drug users in inner-city Sydney. Australian Journal of Primary Health, 17(1), 10-15. [More Information]
• Topp, L., Day, C., Iversen, J., Wand, H., Maher, L. (2011). Fifteen years of HIV surveillance among people who inject drugs: the Australian Needle and Syringe Program Survey 1995-2009. AIDS, 25(6), 835-842. [More Information]
• Chaar, B., Hanrahan, J., Day, C. (2011). Provision of Opioid Substitution Therapy Services in Australian Pharmacies. Australasian Medical Journal, 4(4), 210-216. [More Information]

2010

• Sanson-Fisher, R., Brand, M., Shakeshaft, A., Haber, P., Day, C., Conigrave, K., Mattick, R., Lintzeris, N., Teesson, M. (2010). Forming a national multicentre collaboration to conduct clinical trials: increasing high-quality research in the drug and alcohol field. Drug and Alcohol Review, 29(5), 469-474. [More Information]
• Mofizul Islam, M., Day, C., Conigrave, K. (2010). Harm reduction healthcare: From an alternative to the mainstream platform? International Journal of Drug Policy, 21(2), 131-133. [More Information]
• Day, C., White, B., Dore, G., van Beek, I., Rodgers, C., Cunningham, P., Wodak, A., Maher, L. (2010). Hepatitis B virus among injecting drug users in Sydney, Australia: prevalence, vaccination and knowledge of status. Drug and Alcohol Dependence, 108(40210 (1-2)), 134-137. [More Information]
• Dunn, M., Day, C., Bruno, R., Degenhardt, L., Campbell, G. (2010). Sexual and injecting risk behaviours among regular ecstasy users. Addictive Behaviors, 35(2), 157-160. [More Information]
• Ramasamy, P., Lintzeris, N., Sutton, Y., Taylor, H., Day, C., Haber, P. (2010). The outcome of a rapid hepatitis B vaccination programme in a methadone treatment clinic. Addiction, 105(2), 329-334. [More Information]

2009

• Doab, A., Topp, L., Day, C., Dore, G., Maher, L. (2009). Clinical trial literacy among injecting drug users in Sydney, Australia: A pilot study. Contemporary Clinical Trials, 30(5), 431-435. [More Information]
• Day, C., Haber, P. (2009). Managing drug dependence in people with hepatitis C. In G. Dore, M. Temple-Smith, A. Lloyd (Eds.), Hepatitis C: An Expanding Perspective, (pp. 288-307). East Hawthorn, Victoria: IP Communications.
• Topp, L., Day, C., Dore, G., Maher, L. (2009). Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: A review. Drug and Alcohol Review, 28(6), 669-675. [More Information]
• Coupland, H., Day, C., Levy, M., Maher, L. (2009). Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users. Health Promotion Journal of Australia, 20(3), 234-240. [More Information]

2008

• White, B., Day, C., Thein, H., Doab, A., Bates, A., Holden, J., van Beek, I., Maher, L. (2008). Acceptability of hepatitis C virus testing methods among injecting drug users. Drug and Alcohol Review, 27, 666-670. [More Information]
• Conroy, E., Kimber, J., Dolan, K., Day, C. (2008). An examination of the quality of life among rural and outer metropolitan injecting drug users in NSW, Australia. Addiction Research and Theory, 16(6), 607-617. [More Information]
• Day, C., Topp, L., Iversen, J., Maher, L., Australian NSPs, C. (2008). Blood-borne virus prevalence and risk among steroid injectors: Results from the Australian Needle and Syringe Program Survey. Drug and Alcohol Review, 27(5), 559-561. [More Information]
• Day, C., White, B., Thein, H., Doab, A., Dore, G., Bates, A., Holden, J., Maher, L. (2008). Experience of hepatitis C testing among injecting drug users in Sydney, Australia. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/Hiv, 20(1), 116-123. [More Information]
• O'Brien, S., Day, C., Black, E., Dolan, K. (2008). Injecting drug users' understanding of hepatitis C. Addictive Behaviors, 33(12), 1602-1605. [More Information]
• Topp, L., Iversen, J., Wand, H., Day, C., Kaldor, J., Maher, L. (2008). Representativeness of Injecting Drug Users Who Participate in HIV Surveillance: Results From Australia's Needle and Syringe Program Survey. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 47(5), 632-638. [More Information]

2007

• White, B., Day, C., Maher, L. (2007). Self reported risk behaviour among injecting drug users: Self versus assisted questionnaire completion. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/Hiv, 19(3), 441-447. [More Information]

2006

• Day, C., Degenhardt, L., Hall, W. (2006). Changes in the initiation of heroin use after a reduction in heroin supply. Drug and Alcohol Review, 25(4), 307-313. [More Information]
• Day, C., Dolan, K. (2006). Correlates of hepatitis C testing among heroin injectors in Sydney. Health Promotion Journal of Australia, 17(1), 70-72. [More Information]
• Day, C., Degenhardt, L., Hall, W. (2006). Documenting the heroin shortage in New South Wales. Drug and Alcohol Review, 25(4), 297-305. [More Information]
• Degenhardt, L., Day, C., Conroy, E., Gilmour, S. (2006). Examining Links Between Cocaine Use and Street-Based Sex Work in New South Wales, Australia. Journal of Sex Research, 43(2), 107-114. [More Information]
• Gilmour, S., Koch, I., Degenhardt, L., Day, C. (2006). Identification and quantification of change in Australian illicit drug markets. BMC Public Health, 6, 200-1-200-10. [More Information]
• Conroy, E., Degenhardt, L., Day, C. (2006). Impact of Drug Market Changes on Substance-Using Pregnant Women in Three Key Sydney Drug Markets. Women and Health: the multidisciplinary journal of women's health issues, 44(4), 93-105. [More Information]
• Day, C., Nassirimanesh, B., Shakeshaft, A., Dolan, K. (2006). Patterns of drug use among a sample of drug users and injecting drug users attending a General Practice in Iran. Harm Reduction Journal, 3, 2-1-2-5. [More Information]
• Day, C., Conroy, E., Lowe, J., Page, J., Dolan, K. (2006). Patterns of drug use and associated harms among rural injecting drug users: Comparisons with metropolitan injecting drug users. Australian Journal of Rural Health, 14(3), 120-125. [More Information]
• White, B., Day, C., Degenhardt, L., Kinner, S., Fry, C., Bruno, R., Johnston, J. (2006). Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia. Drug and Alcohol Dependence, 83(3), 210-217. [More Information]
• Degenhardt, L., Day, C., Gilmour, S., Hall, W. (2006). The "lessons" of the Australian "heroin shortage". Substance Abuse Treatment, Prevention, and Policy, 1, 11-1-11-7. [More Information]
• Gilmour, S., Degenhardt, L., Hall, W., Day, C. (2006). Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example. BMC Medical Research Methodology, 6, 16-1-16-9. [More Information]

2005

• Degenhardt, L., Day, C., Conroy, E., Gilmour, S., Hall, W. (2005). Age differentials in the impacts of reduced heroin: Effects of a "heroin shortage" in NSW, Australia. Drug and Alcohol Dependence, 79(3), 397-404. [More Information]
• Degenhardt, L., Day, C., Dietze, P., Pointer, S., Conroy, E., Collins, L., Hall, W. (2005). Effects of a sustained heroin shortage in three Australian States. Addiction, 100(7), 908-920. [More Information]
• Day, C., Ross, J., Dietze, P., Dolan, K. (2005). Initiation to heroin injecting among heroin users in Sydney, Australia: cross sectional survey. Harm Reduction Journal, 2, 2-1-2-7. [More Information]
• Degenhardt, L., Hall, W., Day, C., Dietze, P., Collins, L., Pointer, S. (2005). Mapping the Consequences of an Unanticipated Drug Supply Change of Uncertain Origins: Response to the Commentaries. Addiction, 100(7), 930-932. [More Information]
• Degenhardt, L., Day, C., Gilmour, S., Hall, W. (2005). Patterns of illicit drug use in NSW, Australia following a reduction in heroin supply. International Journal of Drug Policy, 16(5), 300-307. [More Information]
• Shakeshaft, A., Nassirimanesh, B., Day, C., Dolan, K. (2005). Perceptions of substance use, treatment options and training needs among Iranian primary care physicians. International Journal for Equity in Health, 4, 7-1-7-6. [More Information]
• Gibson, A., Degenhardt, L., Day, C., McKetin, R. (2005). Recent trends in heroin supply to markets in Australia, the United States and Western Europe. International Journal of Drug Policy, 16(5), 293-299. [More Information]
• Degenhardt, L., Conroy, E., Day, C., Gilmour, S., Hall, W. (2005). The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. Drug and Alcohol Dependence, 79(2), 129-135. [More Information]
• Day, C., Degenhardt, L., Gilmour, S., Hall, W. (2005). The impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia. BMC Public Health, 5, 84-1-84-8. [More Information]
• Gibson, A., Day, C., Degenhardt, L. (2005). The impact of illicit drug market changes on health agency operations in Sydney, Australia. Journal of Substance Abuse Treatment, 28(1), 35-40. [More Information]
• Degenhardt, L., Day, C., Hall, W., Conroy, E., Gilmour, S. (2005). Was an increase in cocaine use among injecting drug users in New South Wales, Australia, accompanied by an increase in violent crime? BMC Public Health, 5, 40-1-40-10. [More Information]
• Southgate, E., Weatherall, A., Day, C., Dolan, K. (2005). What's in a virus? Folk understandings of hepatitis C infection and infectiousness among injecting drug users in Kings Cross, Sydney. International Journal for Equity in Health, 4, 5-1-5-6. [More Information]

2004

• Day, C., Degenhardt, L., Gilmour, S., Hall, W. (2004). Effects of reduction in heroin supply on injecting drug use: analysis of data from needle and syringe programmes. BMJ: British Medical Journal, 329(7463), 428-429. [More Information]
• Day, C., Jayasuriya, R., Stone, G. (2004). Hepatitis C-related discriminationin New South Wales. Australian Health Review, 27(2), 57-60.
• Day, C., Collins, L., Degenhardt, L., Thetford, C., Maher, L. (2004). Reliability of Heroin Users' Reports of Drug Use Behaviour Using a 24-Month Timeline-Follow-Back Technique to Assess the Impact of the Australian Heroin Shortage. Addiction Research and Theory, 12(5), 433-443. [More Information]

2003

• Lynskey, M., Day, C., Hall, W. (2003). Alcohol and other drug use disorders among older-aged people. Drug and Alcohol Review, 22(2), 125-133.
• Topp, L., Day, C., Degenhardt, L. (2003). Changes in patterns of drug injection concurrent with a sustained reduction in the availability of heroin in Australia. Drug and Alcohol Dependence, 70, 275-286. [More Information]
• Day, C., Ross, J., Dolan, K. (2003). Characteristics of Aboriginal Injecting Drug Users in Sydney, Australia: Prison History, Hepatitis C Status and Drug Treatment Experiences. Journal of Ethnicity in Substance Abuse, 2(3), 51-58. [More Information]
• Topp, L., Degenhardt, L., Day, C., Collins, L. (2003). Contemplating drug monitoring systems in the light of Australia's "heroin shortage" [Editorial]. Drug and Alcohol Review, 22(1), 3-6. [More Information]
• Day, C., Topp, L., Rouen, D., Darke, S., Hall, W., Dolan, K. (2003). Decreased heroin availability in Sydney in early 2001. Addiction, 98(1), 93-95. [More Information]
• Day, C., Ross, J., Dolan, K. (2003). Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination? Drug and Alcohol Review, 22(3), 317-321. [More Information]
• Degenhardt, L., Topp, L., Day, C. (2003). Issues surrounding the detection of a reduction in drug supply: the heroin shortage in Australia in 2001. United Nations. Bulletin on Narcotics, 55(1-2), 131-140.
• Day, C., White, B., Ross, J., Dolan, K. (2003). Poor knowledge and low coverage of hepatitis B vaccination among injecting drug users in Sydney [Letter]. Australian and New Zealand Journal of Public Health, 27(5), 558.
• Day, C., Topp, L. (2003). Safety in drug and alcohol research [Editorial]. Addiction, 98(12), 1641-1643. [More Information]